Abstract
Various trials using non-antiarrhythmic drugs, antiarrhythmic agents and implantable-cardioverter defibrillators (ICDs) have been performed in order to decrease the incidence of sudden death and to improve survival in chronic heart failure (CHF). The present review addresses some of the key findings of those trials. First, it addresses the importance of considering the potential electrophysiological effects of non-antiarrhythmic drugs and of using angiotensin-converting enzyme inhibitors, beta-blockers and antialdosterone agents in the optimal management of patients with CHF. Second, it reviews the effects of the antiarrhythmic agent amiodarone on mortality and arrhythmic deaths in patients with depressed left ventricular function. Third, it assesses the evidence that patients with CHF and a history of sustained ventricular arrhythmias or resuscitation may benefit from ICD implantation. Finally, it outlines the growing role of ICD therapy in patients with CHF as a primary indication.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
